NuVasive (NUVA): Management Meeting Highlights Potential EPS Upside - Piper Jaffray

August 31, 2016 9:28 AM EDT
Get Alerts NUVA Hot Sheet
Price: $69.65 --0%

Rating Summary:
    21 Buy, 14 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 44
Trade NUVA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray analyst Matt O'Brien, reiterated his Overweight rating on shares of NuVasive (NASDAQ: NUVA) after meeting with company management (Greg Lucier (CEO), Carol Cox (EVP Strategy and Corporate Communications) and Micah Young (VP, Finance)) on its bus tour. The analyst stated that the meeting was very upbeat and he views the revenue and, more importantly, the earnings outlook "among the best in all of med tech".

The analyst stated the following two key points:

1) "With negative commentary on the health of the spine market here in Q3, NUVA’s management summarily dismissed that notion with its view on domestic volumes."

2) Management expects to generate $1.6B of annual revenue by 2020. NUVA’s internal annual growth projection of 14% through 2020 (assuming mid-point of 2016 guidance) is much more aggressive than what the Street has modeled at 9% ($1.35B revenue target for 2020).

No change to the price target of $70.

For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.

Shares of NuVasive closed at $65.47 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Piper Jaffray, Earnings

Add Your Comment